title: Using SELDI-TOF mass spectrometry on amniotic fluid and for clinical proteomics and theranostics in disorders of pregnancy.
abstract: Clinical proteomics encompasses a multitude of experimental approaches, tools, and techniques based on proteomics technology which are directly aimed to accelerate and improve diagnosis and treatment of human diseases. Surface-enhanced laser desorption ionization time-of-flight (SELDI-TOF) mass spectrometry is a variant of matrix-enhanced laser desorption ionization (MALDI) that makes use of chemically-modified surfaces to reduce the complexity of biological samples prior to separation in the mass analyzer. Compared to other proteomic techniques, SELDI has several important advantages such as ability to analyze complex biological samples with minimal pre-processing, ease of handling and high throughput. Importantly, once the biomarker or combination of biomarkers with potential clinical value has been established, validation analyses can be conducted in close proximity to clinical settings which is important for establishing the utility of new diagnostics in clinical decision making and perhaps future theranostic interventions. This chapter provides protocols for experimental design and methodology aimed at (1) discovering biologically relevant biomarkers in amniotic fluid using SELDI-TOF; (2) validating the clinical utility of the biomarkers as new diagnostics; (3) translating the biomarker findings into pathophysiological phenomena to provide further insight and extend the current understanding of the disease process. Many of the principles described herein for amniotic fluid could be generalized to studies involving other types of biological samples and other clinical questions.
authors.affiliation: Department of Obstetrics, Gynecology and Reproductive Sciences, Yale University School of Medicine, New Haven, CT, USA. Irina.buhimschi@yale.edu
authors.forename: Irina A
authors.initials: IA
authors.lastname: Buhimschi
mesh_terms: D000653:Amniotic Fluid / Q000737:chemistry*; D015415:Biomarkers / Q000032:analysis; D016022:Case-Control Studies; D019963:Clinical Chemistry Tests / Q000379:methods*; D015331:Cohort Studies; D005260:Female; D006801:Humans; D011247:Pregnancy; D011248:Pregnancy Complications / Q000175:diagnosis* / Q000378:metabolism / Q000628:therapy*; D040901:Proteomics / Q000379:methods*; D012680:Sensitivity and Specificity; D019032:Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization / Q000379:methods*; D013223:Statistics as Topic
chemical_list: D015415:Biomarkers
references.citation: Clin Diagn Lab Immunol. 2005 Jul;12(7):837-44
references.pmid: 16002632
references.citation: BJOG. 2005 Feb;112(2):250-5
references.pmid: 15663594
references.citation: Brief Funct Genomic Proteomic. 2005 Feb;3(4):322-31
references.pmid: 15814023
references.citation: Radiology. 1983 Sep;148(3):839-43
references.pmid: 6878708
references.citation: Obstet Gynecol. 2008 Feb;111(2 Pt 1):403-12
references.pmid: 18238979
references.citation: Am J Obstet Gynecol. 2005 Mar;192(3):710-8
references.pmid: 15746662
references.citation: PLoS One. 2008 Apr 23;3(4):e2049
references.pmid: 18431506
references.citation: Stat Med. 1997 Jul 15;16(13):1529-42
references.pmid: 9249923
references.citation: Placenta. 2008 Mar;29 Suppl A:S95-101
references.pmid: 18191197
references.citation: PLoS Med. 2007 Jan;4(1):e18
references.pmid: 17227133
references.citation: Pediatr Res. 2007 Mar;61(3):318-24
references.pmid: 17314690
references.citation: Am J Obstet Gynecol. 2008 Nov;199(5):551.e1-16
references.pmid: 18984079
references.citation: Am J Obstet Gynecol. 2005 Sep;193(3 Pt 2):957-64
references.pmid: 16157094
references.citation: Int J Gynaecol Obstet. 2005 Jul;90(1):48-50
references.pmid: 15916765
references.citation: BJOG. 2005 Feb;112(2):173-81
references.pmid: 15663581